Cascadian Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib clinical trials, one in combination with T-DM1 and another in combination with capecitabine and/or trastuzumab for the treatment of metastatic breast cancer. The company's product pipeline also includes two preclinical-stage product candidates, which include CASC-578, a Chk1 cell cycle inhibitor; and CASC-674, an antibody against an immuno-oncology target. It has a license agreement with Array BioPharma Inc. to develop, manufacture, and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against immunotherapy targets in oncology. The company was formerly known as Oncothyreon Inc. and changed its name to Cascadian Therapeutics, Inc. in June 2016. Cascadian Therapeutics, Inc. was founded in 1985 and is headquartered in Seattle, Washington. Cascadian Therapeutics, Inc. is a subsidiary of Seattle Genetics, Inc.